MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1086/498024

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2005

The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.

Perlman David C, Segal Yoninah, Rosenkranz Susan, Rainey Petrie M, Remmel Rory P, Salomon Nadim, Hafner Richard, Peloquin Charles A, AIDS Clinical Trials Group 309 Team

Клиническое исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

BACKGROUND

The pharmacokinetics of rifampin and ethambutol in HIV-infected patients with tuberculosis (TB) are incompletely characterized. We examined the pharmacokinetics of rifampin and ethambutol in a cohort of patients with HIV-related TB who were treated in the United States.

METHODS

Serum drug concentrations were determined 2, 6, and 10 h after dosing in 36 HIV-infected patients with TB who were taking rifampin and in 49 who were taking ethambutol. Observed serum concentrations were compared with published normal ranges and published data.

RESULTS

With daily dosing of rifampin (600 mg), 26 (77%) of 34 patients (95% confidence interval [CI], 59%-89%]) had a low maximum concentration of rifampin (<8 microg/mL), and 12 (35%; 95% CI, 20%-54%) had a very low maximum concentration (<4 microg/mL). With intermittent rifampin dosing (600 mg), 13 (68%) of 19 patients (95% CI, 44%-85%) had a low maximum concentration of rifampin, and 5 (26%; 95% CI, 11%-50%) had a very low maximum concentration. With daily ethambutol dosing (20 mg/kg), 33 (69%) of 48 patients (95% CI, 55%-81%) had a low maximum concentration of ethambutol (<2 microg/mL), and 18 (38%; 95% CI, 24%-53%) had a very low maximum concentration (<1 microg/mL). With intermittent ethambutol dosing (50 mg/kg twice weekly or 30 mg/kg thrice weekly), 13 (72%) of 18 patients (95% CI, 47%-88%) had a low maximum concentration of ethambutol (<4 microg/mL), and 5 (28%; 95% CI, 12%-54%]) had a very low maximum concentration (<2 microg/mL).

CONCLUSIONS

In HIV-infected patients with TB who are receiving rifampin and ethambutol, low maximum concentrations of rifampin and ethambutol were common. For patients with HIV-related TB, therapeutic monitoring of rifampin and ethambutol levels may help clinicians achieve target serum concentrations.

Для цитирования: Perlman David C, Segal Yoninah, Rosenkranz Susan, Rainey Petrie M, Remmel Rory P, Salomon Nadim, Hafner Richard, Peloquin Charles A, AIDS Clinical Trials Group 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2005. DOI: 10.1086/498024.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.